Tepezza

News

Dyvyzat box, bottle, and oral delivery mechanism.

Italfarmaco closes on EU okay for Duchenne drug

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

News

Sling shoots at thyroid eye disease with its oral therapy

Amgen's thyroid eye disease blockbuster Tepezza, given by infusion, is facing competition from an oral alternative from Sling Therapeutics.

News

Viridian takes aim at Amgen's Tepezza with veligrotug data

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian

Italfarmaco closes on EU okay for Duchenne drug

Sling shoots at thyroid eye disease with its oral therapy

Viridian takes aim at Amgen's Tepezza with veligrotug data

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

Using AI-driven synthetic personas to take your insights fur...

Editor's Picks